(Q84324837)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

main subject

hepatocellular carcinoma

1 reference

1

David J Pinato

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Rohini Sharma

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

30 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

160

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

146-152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

Novel advancements in the management of hepatocellular carcinoma in 2008.

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Loco-regional treatment of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Management of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Chronic inflammation and hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

The causes and consequences of cancer-associated malnutrition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Use of inflammatory markers to guide cancer treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Diagnosis and Treatment of Hepatocellular Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Inflammation and liver cancer: new molecular links .

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.011

10.1016/J.TRSL.2012.01.011

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22677364%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference